Annabell Wolff

Annabell Wolff

Auto-generated profile, based on publicly available information

Annabell Wolff

Department of Internal Medicine-Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Rostock, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AWAnnabell Wolff
Annabell Wolff
GWGrit Waitz
Grit Waitz
PKPhilipp Kaps
Philipp Kaps
SOSonja Oehmcke-Hecht
Sonja Oehmcke-Hecht
WBWendy Bergmann-Ewert
Wendy Bergmann-Ewert
CMClaudia Maletzki
Claudia Maletzki
Glioblastoma (GBM) is often complicated by venous thromboembolism (VTE), primarily driven by tissue factor (TF, F3 ) and podoplanin (PDPN). These factors promote local hypercoagulation and microthrombosis, thereby contributing to tumor progression by enhancing migration, invasion, and inflammation. Both TF and PDPN can be released via extracellular vesicles (EVs), which carry procoagulant and immunomodulatory cargo. We developed a translational workflow combining biobanked tumor samples, clinical data, ex vivo GBM cultures, and coagulation assays to investigate mechanisms of hypercoagulation. Intraoperative blood coagulation was profiled using ClotPro ® . Gene expression of coagulation-related markers was analyzed in tumor tissues and cell lines, complemented by RNAseq-based profiling of coagulation–inflammation links. Functional coagulation assays included clotting time, platelet aggregation, and EV-based analysis of prothrombotic and immunomodulatory activity. Peripheral coagulation in GBM patients was largely unaltered. However, tumor tissues consistently showed high F3 and PDPN expression and markedly low tissue factor pathway inhibitor ( TFPI ) levels ( p < 0.001), indicating a shift toward a procoagulant phenotype. Patient-derived GBM cell lines showed variable TF and PDPN expression, which correlated with clotting potential. Distinct procoagulant mechanisms were observed, with some cells engaging both TF-mediated thrombin generation and PDPN-driven platelet activation. EVs isolated from GBM patient plasma and culture media showed similar procoagulant characteristics, with activity proportional to TF expression, and immune-modulating effects. Notably, GBM-derived EVs modulated microglial behavior, induced senescence, and triggered immune polarization in a cell line-dependent manner, likely contributing to tumor microenvironment remodeling. GBM-associated hypercoagulability is shaped by heterogeneous tumor-intrinsic pathways and EV-mediated mechanisms. The dual role of EVs in promoting coagulation and modulating immune responses provides a mechanistic framework for further studies investigating EVs as potential biomarkers and therapeutic targets relevant to future thromboprophylactic strategies in GBM patients.

16 July 2025 in Translational Oncology
Verified
Journal Article
Open access
AWAnnabell Wolff
Annabell Wolff
JMJohanna Maennicke
Johanna Maennicke
MHMaja Hühns
Maja Hühns
PKPaula Krone
Paula Krone
SOSonja Oehmcke-Hecht
Sonja Oehmcke-Hecht
CMClaudia Maletzki
Claudia Maletzki
FDA-approved immune checkpoint inhibitors (ICIs) are the state-of-the-art treatment for mismatch-repair deficient tumors (dMMR). Their immunomodulatory effects in a preventive setting, are poorly studied. In this study, we used two ICIs against PD-L1 or LAG-3 in a preclinical mouse model of dMMR-driven carcinogenesis. Msh2loxP/loxP; TgTg(Vil1-cre mice without clinical signs of tumor development (i.e. age <12 weeks) received repeated applications (n = 8, 28-day interval) of anti-PD-L1, anti-LAG-3 (2.5 mg/kg bw, i.p.) or isotype (anti-IgG1, 2.5 mg/kg bw, i.p.). Blood phenotyping, tumor microenvironment, and hematopoiesis, and presence of procoagulant extracellular vesicles (EV) were studied. Prophylactic ICI application significantly prolonged overall survival (OS) of Msh2loxP/loxP; TgTg(Vil1-cre mice (OS: anti-PD-L1: 54.4 wks and anti-LAG-3: 58.4 wks vs. ctrl 35.8 wks). Circulating exhausted and regulatory T cells were significantly lower in the ICI groups. Splenic exhaustion markers showed correlating results. Outgrowing tumors showed an inflammatory response-related gene signature. Accompanying immunofluorescence confirmed data and identified reduced numbers of tumor-infiltrating regulatory granulocytes in late-onset tumors. Alterations in bone marrow hematopoiesis accompanied this massive immune modulation, indicating successful prevention of myeloid-shifted hematopoiesis. Plasma coagulation of EVs was not significantly altered in the ICI groups. Preventive ICI prolongs overall survival of cancer-prone mice. The sustained immune modulation and normal bone marrow hematopoiesis may pre-sensitize late-onset dMMR tumors to a second round of immunotherapy. Hence, we highlight the importance of preventive strategies for germline MMR mutation carriers and recommend improved screening of patients eligible for prophylactic ICIs to improve long-term outcomes.

6 June 2026 in Immuno-Oncology and Technology
Verified
Journal Article
Open access
PMP. Meißner
P. Meißner
PKP. Kaps
P. Kaps
TMT. Momper
T. Momper
AWA. Wolff
A. Wolff
IRI. Raabe
I. Raabe
CMClaudia Maletzki
Claudia Maletzki
Immune checkpoint inhibitor (ICI) therapy improves survival in head and neck squamous cell carcinoma (HNSCC), yet only some patients benefit, highlighting the need for early identification of responders and functional evaluation of tumor–immune interactions. We developed an autologous coculture platform combining patient-derived organoids (PDOs) with peripheral blood mononuclear cells (PBMCs) to assess immune responses and correlate preclinical findings with clinical outcomes. PDOs from HNSCC specimens were expanded and cocultured with PBMCs, followed by treatment with ICIs targeting programmed cell death protein 1 (PD-1), lymphocyte-activation gene 3 (LAG-3), or their combination. PBMCs were enriched for CD4+ and CD8+ T cells (∼90%) and CD16+CD56+ natural killer cells, with baseline exhaustion (LAG-3+, CTLA-4+). T cell–mediated tumor killing occurred in 44% of cases and was accompanied by Th1/Th17 cytokine signatures. ICI treatment modestly shifted T-cell phenotypes, reducing exhaustion (PD-1) and enriching cytolytic subsets (CD4+IFN-γ+, CD8+TOX+). Interleukin (IL)-17A emerged as a relevant cytokine, correlating with FasL secretion and suggesting activation of the Fas/FasL axis. High circulating IL-17A levels in treatment-naïve HNSCC patients were associated with improved survival, whereas other cytokines showed no prognostic value. In a noninterventional observational trial, increases in IL-17A positively correlated with favorable ICI responses, indicating its potential as a biomarker. PDO viability decreased in response to ICIs in a patient-specific manner, consistent with cytokine signatures and clinical outcomes. Collectively, this autologous PDO–PBMC coculture platform, combined with longitudinal cytokine profiling, captures patient-specific tumor–immune interactions and interpatient heterogeneity, providing a framework for real-time response prediction, biomarker discovery, and personalized immunotherapy in HNSCC.

30 May 2026 in Cellular and Molecular Neurobiology
Verified
Journal Article
Open access
KRKatharina Richter
Katharina Richter
HMHannah Markmann
Hannah Markmann
PKPhilipp Kaps
Philipp Kaps
AWAnnabell Wolff
Annabell Wolff
SSStefan Simm
Stefan Simm
BSBjoern Schneider
Bjoern Schneider
MicroRNAs (miRNAs) play pivotal roles in glioblastoma (GBM) progression and therapy resistance. Among them, miR-25-3p has emerged as a key oncogenic miRNA that promotes tumor growth, invasiveness, and resistance to temozolomide (TMZ). In this study, we profiled miRNA expression in primary GBM specimens ( n = 50) stratified by MGMT methylation and TP53 mutation status and assessed the functional impact of miR-25-3p inhibition in seven patient-derived GBM cell lines. Quantitative PCR analysis revealed upregulation of miR-135b in MGMT -methylated tumors and miR-10b in TP53 -mutant cases. Both miR-25-3p and miR-10b were significantly elevated in 3D spheroid cultures compared to 2D monolayers. Notably, both miRNAs were secreted via tumor-derived extracellular vesicles, implicating a role in cell-cell communication. Inhibition of miR-25-3p in GBM cell lines consistently suppressed β-catenin and re-induced FBXW7 expression across all cases, correlating with inhibitor uptake. In four of seven cell lines, miR-25-3p inhibition enhanced TMZ sensitivity and reduced invasiveness, although the anti-invasive effect was not further potentiated by the addition of TMZ. In addition, RNA-Seq and methylome analyses revealed genetic and epigenetic reprograming toward a less aggressive, less invasive phenotype with reduced stemness potential. These findings highlight the interplay between tumor microenvironment and molecular heterogeneity in shaping miRNA dynamics in GBM. Collectively, our results identify miR-25-3p as a promising dual-action therapeutic target to mitigating both invasion and chemoresistance in GBM, warranting further translational investigation. Graphical miRNA-mediated regulation of invasion, protein synthesis, and drug sensitivity in glioblastoma. Schematic overview of miRNA-mediated regulation of glioblastoma cell behavior. miRNAs modulate mRNA targets and protein synthesis, influencing β-catenin signaling, invasion capacity, and temozolomide sensitivity through FBXW7-associated pathways, ultimately affecting apoptosis.